Keros Therapeutics (NASDAQ:KROS) Stock Rating Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen cut shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a research note released on Sunday morning,Wall Street Zen reports.

Several other research analysts also recently issued reports on KROS. Wells Fargo & Company cut their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Finally, Leerink Partners reduced their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $20.50.

Keros Therapeutics Stock Performance

KROS stock opened at $11.04 on Friday. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The company has a market capitalization of $218.92 million, a price-to-earnings ratio of -2.98 and a beta of 1.13. The business’s 50 day moving average price is $11.27 and its two-hundred day moving average price is $12.14.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Sell-side analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its board has authorized a stock buyback plan on Wednesday, September 9th that allows the company to repurchase $5 million in outstanding shares. This buyback authorization allows the company to reacquire up to 2.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.

Insider Activity at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares of the company’s stock, valued at $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 5,343 shares of company stock worth $54,985. 12.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KROS. BlackRock Inc. bought a new position in shares of Keros Therapeutics in the second quarter valued at approximately $29,898,000. Nantahala Capital Management LLC purchased a new stake in shares of Keros Therapeutics in the second quarter worth approximately $15,091,483. Dimensional Fund Advisors LP raised its stake in shares of Keros Therapeutics by 453.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock worth $3,547,000 after acquiring an additional 263,347 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in Keros Therapeutics in the 2nd quarter worth approximately $2,641,000. Finally, Y Intercept Hong Kong Ltd increased its holdings in shares of Keros Therapeutics by 40.2% in the first quarter. Y Intercept Hong Kong Ltd now owns 164,483 shares of the company’s stock valued at $1,816,000 after purchasing an additional 47,122 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-?) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.